Evidence map›Paper›PMID 38014161›Full record

ArticlebioRxiv : the preprint server for biology2023

An engineered glioblastoma model yields novel macrophage-secreted drivers of invasion.

Erin A Akins, Dana Wilkins, Manish K Aghi, Sanjay Kumar

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erin A AkinsUniversity of California, Berkeley - University of California, San Francisco Graduate Program in Bioengineering, Berkeley, CA, USA.ORCID 0000-0002-5359-5891
Dana WilkinsUniversity of California, Berkeley - University of California, San Francisco Graduate Program in Bioengineering, Berkeley, CA, USA.
Manish K AghiDepartment of Neurosurgery; University of California San Francisco (UCSF).ORCID 0000-0002-2949-2227
Sanjay KumarUniversity of California, Berkeley - University of California, San Francisco Graduate Program in Bioengineering, Berkeley, CA, USA.
University of California, San Francisco · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo, FREDERICK F LANG · 2008 to 2026
$41.2M
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for GlioblastomaR01CA247970 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LANG, FREDERICK F · 2020 to 2024
$2.2M
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systemsR01CA227136 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2018 to 2022
$2.2M
Retroviral RLI immunomodulatory gene therapy for glioblastomaR01NS123808 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Manish Aghi · 2022 to 2026
$2.1M
MSC-Derived Exosomes and MicroRNA in Glioma TherapyR01CA214749 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LANG, FREDERICK F · 2018 to 2022
$1.8M
Mechanisms of adhesion and invasion in hyaluronic acid matricesR01CA260443 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI KUMAR, SANJAY · 2021 to 2025
$1.8M
LTQ XL Linear Quadrupole Ion Trap Mass SpectrometerS10RR025622 · NCRR · UNIVERSITY OF CALIFORNIA BERKELEY · PI KOHLSTAEDT, LORI · 2009 to 2009
$463k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA214749NCI NIH HHS R01 CA227136NCI NIH HHS R01 CA247970NCI NIH HHS R01 CA260443NCRR NIH HHS S10 RR025622NINDS NIH HHS R01 NS123808
6 · The paper itself

Abstract

Glioblastomas (GBMs) are highly invasive brain tumors replete with brain- and blood-derived macrophages, collectively known as tumor-associated macrophages (TAMs). Targeting TAMs has been proposed as a therapeutic strategy but has thus far yielded limited clinical success in slowing GBM progression, due in part to an incomplete understanding of TAM function in GBM. Here, by using an engineered hyaluronic acid-based 3D invasion platform, patient-derived GBM cells, and multi-omics analysis of GBM tumor microenvironments, we show that M2-polarized macrophages stimulate GBM stem cell (GSC) mesenchymal transition and invasion. We identify TAM-derived transforming growth factor beta induced (TGFβI/BIGH3) as a pro-tumorigenic factor in the GBM microenvironment. In GBM patients, BIGH3 mRNA expression correlates with poor patient prognosis and is highest in the most aggressive GBM molecular subtype. Inhibiting TAM-derived BIGH3 signaling with a blocking antibody or small molecule inhibitor suppresses GSC invasion. Our work highlights the utility of 3D

Identifiers

PMID38014161
PMCPMC10680873
OpenAlexW4388811371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.